Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

por Tolar, Martin, Hey, John, Power, Aidan, Abushakra, Susan
Publicado 2021

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

por Tolar, Martin, Abushakra, Susan, Hey, John A., Porsteinsson, Anton, Sabbagh, Marwan
Publicado 2020

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

por Hey, John A., Kocis, Petr, Hort, Jakub, Abushakra, Susan, Power, Aidan, Vyhnálek, Martin, Yu, Jeremy Y., Tolar, Martin
Publicado 2018

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease

por Hey, John A., Yu, Jeremy Y., Versavel, Mark, Abushakra, Susan, Kocis, Petr, Power, Aidan, Kaplan, Paul L., Amedio, John, Tolar, Martin
Publicado 2017

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

por Abushakra, Susan, Porsteinsson, Anton P., Sabbagh, Marwan, Bracoud, Luc, Schaerer, Joel, Power, Aidan, Hey, John A., Scott, David, Suhy, Joyce, Tolar, Martin
Publicado 2020